[Pulmonary arterial hypertension and chronic obstructive bronchopneumopathy]

Area of Science:

• Pulmonary Medicine
• Cardiology
• Respiratory Physiology

Background:

• Chronic obstructive lung disease (COPD) frequently complicates with pulmonary arterial hypertension (PAH).
• PAH in COPD is a primary driver of chronic cor pulmonale.
• Increased pulmonary vascular resistance due to chronic hypoxia is the main cause of PAH in COPD.

Purpose of the Study:

• To highlight the clinical significance of pulmonary arterial pressure (PAP) in COPD.
• To underscore the lack of accurate non-invasive methods for PAP measurement.
• To discuss the progressive nature of PAP elevation in COPD and its prognostic value.

Main Methods:

• This abstract discusses the pathophysiology and clinical course of PAH in COPD.
• It reviews the limitations of current diagnostic methods for PAP.
• It references the epidemiological data on PAP progression and mortality in COPD patients.

Main Results:

• Pulmonary arterial pressure (PAP) increases gradually in COPD, approximately 0.5 to 0.6 mmHg annually.
• PAP is a critical mortality predictor in COPD, second only to FEV1.
• The efficacy of targeted vasodilators for PAH in COPD has not been established.

Conclusions:

• Pulmonary arterial hypertension is an inevitable complication of COPD, significantly impacting prognosis.
• Accurate, non-invasive monitoring of PAP is crucial for managing COPD patients.
• Further research is needed to establish effective therapeutic strategies, including the role of vasodilators.